XNAS
VCRE
Market cap252mUSD
Oct 14, Last price
9.08USD
1D
1.45%
1Q
-22.39%
IPO
-44.12%
Name
Vicore Pharma Holding AB
Chart & performance
P/E
—
P/S
6,699.94
EPS
—
Div yield, %
—
Shs. 5Y
-15.06%
Rev. 5Y
-11.73%
Revenues
4m
-96.51%
Net income
-477m
L+183.14%
CFO
-376m
L+127.79%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
Key people
Ahmed Mousa
Chief Executive Officer · since 2023
Hans Jeppsson
Chief Financial Officer · since 2017
Nina Carlen
Chief Administrative Officer · since 2009
Johan Raud
Chief Scientific Officer · since 2018
Helen Barker
Vice President and Head of CMC · since 2024
Mikael Nygard
Vice President - Operations and Corporate Strategy · since 2023
Megan Richards
Vice President - Investor Relations, Communications and Portfolio Strategy · since 2024
Elin Rosendahl
Vice President - Clinical Development · since 2020
Jimmie Hofman
Vice President - Business Development · since 2024
Johanna Graens
Program Director - Early Development · since 2022
Bertil Lindmark
Chief Medical Officer · since 2024
Asa Magnusson
Chief Engagement and Commercial Officer · since 2024
Jessica Shull
Head of Digital Health · since 2021
Independent Chairman of the Board · since 2024
Yasir Al Wakeel
Independent Director · since 2024
Ann Barbier
Independent Director · since 2024
Independent Director · since 2023
Michael Buschle
Independent Director · since 2023
Jacob Gunterberg
Independent Director · since 2024
Heidi Hunter
Independent Director · since 2020
Headquarters & legal address
Postbox 14
Göteborg, O 414 52
SE
Göteborg, O 414 52
SE
Address
Postbox 14
Goteborg, O 414 52
SE
Goteborg, O 414 52
SE
Previous name
Mintage Scientific AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||